Associate Professor Rosemary Balleine

Clinical Associate Professor
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical Research

Telephone 9845 8086
Fax 9845 9102

Map

Selected grants

2012

  • A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study); Gurney H, Balleine R, Wilcken N, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • Investigating the role of microRNAs in breast cancer progression; Soon P, Balleine R, Clarke C, Pathmanathan N; National Breast Cancer Foundation/Pilot Study Grants.
  • Breast cancer biospecimen resource; Morey A, Forbes J, Scott R, Spigelman A, Clarke C, Kefford R, Baxter R, Marsh D, Friedlander M, Harnett P, Balleine R, Bilous M, Boyages J, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2009

  • Breast Cancer Tissue Bank - data collection and management infrasture; Clarke C, Scott R, Balleine R, Carpenter J, Baxter R, Bilous M, Lee S, Marsh D, Scott R, Spigelman A; Cancer Institute New South Wales/Infrastructure Grant.
  • Molecular grade as prognostic indicator in invasive breast cancer; Balleine R; Cancer Institute New South Wales/Clinical Research Fellowship (CRF).
  • High-Throughput virtual microscopy and data warehouse system; Mann G, Schifter M, Balleine R, George J, Henderson B, Clarke C, Catchpoole D, deFazio A; Cancer Institute New South Wales/Equipment Grant.

2007

  • Tracing the origin of variable malignant potential in breast cancer; Balleine R, Clarke C; University of Sydney/Cancer Research Fund.
  • Breast Cancer Tissue Bank; Marsh D, Clarke C, Scott R, Kefford R, Balleine R, Baxter R, Bilous M, Carpenter J, Friedlander M, Forbes J, Boyages J, Spigelman A, Sutherland R, Harnett P, Morey A; National Breast Cancer Foundation/Research Grants.
  • Breast cancer biospecimen resource; Kefford R, Balleine R, Baxter R, Clarke C, Bilous M; National Breast Cancer Foundation/Facilitation Grant.

2006

  • Insights Into Mechanisms Of Breast Cancer Pathogenesis From Tissue Pathology; Balleine R; Cancer Institute New South Wales/Research Support.
  • University of Sydney - Cancer Research Fund; Balleine R; University of Sydney/Cancer Research Fund.

2005

  • Breast Cancer biospecimen resource; Boyages J, Spigelman A, Forbes J, Marsh D, Friedlander M, Morey A, Spigelman A, Sutherland R, Scott R, Balleine R, Baxter R, Bilous M, Kefford R, Clarke C; National Breast Cancer Foundation/Grant-in-Aid.
  • Breast cancer biospecimen resource; Marsh D, Clarke C, Harnett P, Spigelman A, Forbes J, Harnett P, Friedlander M, Sutherland R, Boyages J, Morey A, Spigelman A, Scott R, Balleine R, Baxter R, Bilous M, Kefford R; Cancer Institute New South Wales/Research Grant.

2004

  • Determination of diagnostic molecular profiles for intraduct lesions of the breast.; Balleine R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Breast cancer biospecimen resource; Clarke C, Balleine R, Bilous M, Kefford R, Baxter R, Harnett P, Spigelman A, Forbes J, Spigelman A, Marsh D, Boyages J, Friedlander M, Harnett P, Morey A, Scott R, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2002

  • Determination of diagnostic molecular profiles for intraduct lesions of the breast; Balleine R; Leo and Jenny Leukaemia and Cancer Foundation/Research Support.

2000

  • Early events predisposing to breast cancer in women with a genetic susceptibility; Clarke C, Leary J, Balleine R, Kirk J; Leo and Jenny Leukaemia and Cancer Foundation/Leukaemia and Cancer Foundation.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., Hung, J., Chiew, Y., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 4, 1-9. [More Information]
  • Pathmanathan, N., Balleine, R., Jayasinghe, U., Stalgis-Bilinski, K., Provan, P., Byth Wilson, K., Bilous, M., Salisbury, E., Boyages, J. (2014). The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. Journal of Clinical Pathology, 67(3), 222-228. [More Information]
  • Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhie, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45(4), 392-398. [More Information]
  • Pathmanathan, N., Balleine, R. (2013). Ki67 and proliferation in breast cancer. Journal of Clinical Pathology, 66(6), 512-516. [More Information]
  • Webster, L., Provan, P., Graham, J., Byth Wilson, K., Walker, R., Davis, S., Salisbury, E., Morey, A., Ward, R., Hawkins, N., Clarke, C., Balleine, R., et al (2013). Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology, 45(7), 629-636. [More Information]
  • Pathmanathan, N., Provan, P., Mahajan, H., Hall, G., Byth Wilson, K., Bilous, M., Balleine, R. (2012). Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. The Breast, 21(6), 724-729. [More Information]
  • Khushi, M., Carpenter, J., Balleine, R., Clarke, C. (2012). Development of a data entry auditing protocol and quality assurance for a tissue bank database. Cell and Tissue Banking, 13(1), 9-13. [More Information]
  • Khushi, M., Carpenter, J., Balleine, R., Clarke, C. (2012). Electronic Biorepository Application System: Web-Based Software to Manage Receipt, Peer Review, and Approval of Researcher Applications. Biopreservation and Biobanking, 10(1), 37-44. [More Information]
  • Balleine, R., Wilcken, N. (2012). High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. Molecular Diagnosis and Therapy, 16(4), 235-240. [More Information]
  • Haiman, C., Chen, G., Vachon, C., Canzian, F., Dunning, A., Millikan, R., Wang, X., Ademuyiwa, F., Ahmed, S., Ambrosone, C., Balleine, R., Carpenter, J., Clarke, C., et al (2011). A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 43(12), 1210-1215. [More Information]
  • Stevens, K., Vachon, C., Lee, A., Slager, S., Lesnick, T., Oswald, C., fasching, P., Miron, P., Carpenter, J., Clarke, C., Balleine, R., et al (2011). Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 71(19), 6240-6249. [More Information]
  • Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS One, 6(3), e17617-1-e17617-18. [More Information]
  • Houssami, N., Macaskill, P., Balleine, R., Bilous, M., Pegram, M. (2011). HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment, 129(3), 659-674. [More Information]
  • Pathmanathan, N., Salisbury, E., Provan, P., Bilous, M., Byth Wilson, K., Milliken, J., Clarke, C., Balleine, R. (2010). A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast. Pathology, 42(1), 28-36. [More Information]
  • Spurdle, A., Lakhani, S., Da Silva, L., Balleine, R., kConFab Investigators., Goldgar, D. (2010). Bayes Analysis Provides Evidence of Pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) Variants Displaying In Vitro Splicing Results of Equivocal Clinical Significance. Human Mutation, 31(2), E1141-E1145. [More Information]
  • Pathmanathan, N., Albertini, A., Provan, P., Milliken, J., Salisbury, E., Bilous, M., Byth Wilson, K., Balleine, R. (2010). Diagnostic evaluation of papillary lesions of the breast on core biopsy. Modern Pathology, 23(7), 1021-1028. [More Information]
  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Da Silva, L., Simpson, P., Smart, C., Cocciardi, S., Waddell, N., Lane, A., Morrison, B., Vargas, A., Healey, S., Beesley, J., Bilous, M., Balleine, R., et al (2010). HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research, 12(4), R46-1-R46-12. [More Information]
  • Graham, J., Mote, P., Salagame, U., Van Dijk, J., Balleine, R., Huschtscha-Holliday, L., Reddel, R., Clarke, C. (2009). DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology, 150(7), 3318-3326. [More Information]
  • Graham, J., Mote, P., Salagame, U., Balleine, R., Huschtscha-Holliday, L., Clarke, C. (2009). Hormone-Responsive Model of Primary Human Breast Epithelium. Journal of Mammary Gland Biology and Neoplasia, 14(4), 367-379. [More Information]
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Loughrey, M., Provan, P., Byth Wilson, K., kConFab Investigators., Balleine, R. (2008). Histopathological features of ''BRCAX'' familial breast cancers in the kConFab resource. Pathology, 40(4), 352-358.
  • Balleine, R., Webster, L., Davis, S., Salisbury, E., Palazzo, J., Schwartz, G., Cornfield, D., Walker, R., Byth Wilson, K., Clarke, C., et al (2008). Molecular Grading of Ductal Carcinoma In situ of the Breast. Clinical Cancer Research, 14(24), 8244-8252. [More Information]
  • Balleine, R., Bilous, M., Morey, A. (2008). Painting by numbers: The power and peril of synoptic pathology reporting for cancer. Asia-Pacific Journal of Clinical Oncology, 4(2), 75-76.
  • Webster, L., Lee, S., Ringland, C., Morey, A., Hanby, A., Morgan, G., Byth Wilson, K., Mote, P., Provan, P., Ellis, I., Lamoury, G., Clarke, C., Balleine, R., et al (2008). Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Clinical Cancer Research, 14(20), 6625-6633. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Balleine, R., Murali, R., Bilous, M., Farshid, G., Waring, P., Provan, P., Byth Wilson, K., Thorne, H., KConFab, C., Kirk, J. (2006). Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology, 49. [More Information]
  • Farshid, G., Balleine, R., Cummings, M., Waring, P., The Kathleen Cunningham Consortium for Research into Familial Breast Cancer. (2006). Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing. American Journal of Surgical Pathology, 30(11), 1357-1366. [More Information]
  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology and Therapeutics, 77(1), 33-42. [More Information]
  • Webster, L., Bilous, M., Willis, L., Byth Wilson, K., Burgemeister, F., Salisbury, E., Clarke, C., Balleine, R. (2005). Histopathologic indicators of breast cancer biology: insights from population mammographic screening. British Journal of Cancer, 92(8), 1366-1371. [More Information]
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. Pharmacology and Therapeutics, 75(6), 529-538. [More Information]
  • Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 23(2), 138-144.
  • Balleine, R., Humphrey, K., Clarke, C. (2001). Tumour banks: providing human tissue for cancer research. Medical Journal of Australia, 175, 293-294.
  • Mote, P., Balleine, R., McGowan, E., Clarke, C. (2000). Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Human Reproduction, 15(supp3), 48-56.
  • Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes and Cancer, 29(1), 48-57.

2014

  • Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., Hung, J., Chiew, Y., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 4, 1-9. [More Information]
  • Pathmanathan, N., Balleine, R., Jayasinghe, U., Stalgis-Bilinski, K., Provan, P., Byth Wilson, K., Bilous, M., Salisbury, E., Boyages, J. (2014). The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. Journal of Clinical Pathology, 67(3), 222-228. [More Information]

2013

  • Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhie, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45(4), 392-398. [More Information]
  • Pathmanathan, N., Balleine, R. (2013). Ki67 and proliferation in breast cancer. Journal of Clinical Pathology, 66(6), 512-516. [More Information]
  • Webster, L., Provan, P., Graham, J., Byth Wilson, K., Walker, R., Davis, S., Salisbury, E., Morey, A., Ward, R., Hawkins, N., Clarke, C., Balleine, R., et al (2013). Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology, 45(7), 629-636. [More Information]

2012

  • Pathmanathan, N., Provan, P., Mahajan, H., Hall, G., Byth Wilson, K., Bilous, M., Balleine, R. (2012). Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. The Breast, 21(6), 724-729. [More Information]
  • Khushi, M., Carpenter, J., Balleine, R., Clarke, C. (2012). Development of a data entry auditing protocol and quality assurance for a tissue bank database. Cell and Tissue Banking, 13(1), 9-13. [More Information]
  • Khushi, M., Carpenter, J., Balleine, R., Clarke, C. (2012). Electronic Biorepository Application System: Web-Based Software to Manage Receipt, Peer Review, and Approval of Researcher Applications. Biopreservation and Biobanking, 10(1), 37-44. [More Information]
  • Balleine, R., Wilcken, N. (2012). High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. Molecular Diagnosis and Therapy, 16(4), 235-240. [More Information]

2011

  • Haiman, C., Chen, G., Vachon, C., Canzian, F., Dunning, A., Millikan, R., Wang, X., Ademuyiwa, F., Ahmed, S., Ambrosone, C., Balleine, R., Carpenter, J., Clarke, C., et al (2011). A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 43(12), 1210-1215. [More Information]
  • Stevens, K., Vachon, C., Lee, A., Slager, S., Lesnick, T., Oswald, C., fasching, P., Miron, P., Carpenter, J., Clarke, C., Balleine, R., et al (2011). Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 71(19), 6240-6249. [More Information]
  • Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS One, 6(3), e17617-1-e17617-18. [More Information]
  • Houssami, N., Macaskill, P., Balleine, R., Bilous, M., Pegram, M. (2011). HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment, 129(3), 659-674. [More Information]

2010

  • Pathmanathan, N., Salisbury, E., Provan, P., Bilous, M., Byth Wilson, K., Milliken, J., Clarke, C., Balleine, R. (2010). A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast. Pathology, 42(1), 28-36. [More Information]
  • Spurdle, A., Lakhani, S., Da Silva, L., Balleine, R., kConFab Investigators., Goldgar, D. (2010). Bayes Analysis Provides Evidence of Pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) Variants Displaying In Vitro Splicing Results of Equivocal Clinical Significance. Human Mutation, 31(2), E1141-E1145. [More Information]
  • Pathmanathan, N., Albertini, A., Provan, P., Milliken, J., Salisbury, E., Bilous, M., Byth Wilson, K., Balleine, R. (2010). Diagnostic evaluation of papillary lesions of the breast on core biopsy. Modern Pathology, 23(7), 1021-1028. [More Information]
  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Da Silva, L., Simpson, P., Smart, C., Cocciardi, S., Waddell, N., Lane, A., Morrison, B., Vargas, A., Healey, S., Beesley, J., Bilous, M., Balleine, R., et al (2010). HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research, 12(4), R46-1-R46-12. [More Information]

2009

  • Graham, J., Mote, P., Salagame, U., Van Dijk, J., Balleine, R., Huschtscha-Holliday, L., Reddel, R., Clarke, C. (2009). DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology, 150(7), 3318-3326. [More Information]
  • Graham, J., Mote, P., Salagame, U., Balleine, R., Huschtscha-Holliday, L., Clarke, C. (2009). Hormone-Responsive Model of Primary Human Breast Epithelium. Journal of Mammary Gland Biology and Neoplasia, 14(4), 367-379. [More Information]

2008

  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Loughrey, M., Provan, P., Byth Wilson, K., kConFab Investigators., Balleine, R. (2008). Histopathological features of ''BRCAX'' familial breast cancers in the kConFab resource. Pathology, 40(4), 352-358.
  • Balleine, R., Webster, L., Davis, S., Salisbury, E., Palazzo, J., Schwartz, G., Cornfield, D., Walker, R., Byth Wilson, K., Clarke, C., et al (2008). Molecular Grading of Ductal Carcinoma In situ of the Breast. Clinical Cancer Research, 14(24), 8244-8252. [More Information]
  • Balleine, R., Bilous, M., Morey, A. (2008). Painting by numbers: The power and peril of synoptic pathology reporting for cancer. Asia-Pacific Journal of Clinical Oncology, 4(2), 75-76.
  • Webster, L., Lee, S., Ringland, C., Morey, A., Hanby, A., Morgan, G., Byth Wilson, K., Mote, P., Provan, P., Ellis, I., Lamoury, G., Clarke, C., Balleine, R., et al (2008). Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Clinical Cancer Research, 14(20), 6625-6633. [More Information]

2007

  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology and Therapeutics, 82(1), 33-40. [More Information]

2006

  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Balleine, R., Murali, R., Bilous, M., Farshid, G., Waring, P., Provan, P., Byth Wilson, K., Thorne, H., KConFab, C., Kirk, J. (2006). Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology, 49. [More Information]
  • Farshid, G., Balleine, R., Cummings, M., Waring, P., The Kathleen Cunningham Consortium for Research into Familial Breast Cancer. (2006). Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing. American Journal of Surgical Pathology, 30(11), 1357-1366. [More Information]
  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]

2005

  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology and Therapeutics, 77(1), 33-42. [More Information]
  • Webster, L., Bilous, M., Willis, L., Byth Wilson, K., Burgemeister, F., Salisbury, E., Clarke, C., Balleine, R. (2005). Histopathologic indicators of breast cancer biology: insights from population mammographic screening. British Journal of Cancer, 92(8), 1366-1371. [More Information]
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]

2004

  • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. Pharmacology and Therapeutics, 75(6), 529-538. [More Information]
  • Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 23(2), 138-144.

2001

  • Balleine, R., Humphrey, K., Clarke, C. (2001). Tumour banks: providing human tissue for cancer research. Medical Journal of Australia, 175, 293-294.

2000

  • Mote, P., Balleine, R., McGowan, E., Clarke, C. (2000). Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Human Reproduction, 15(supp3), 48-56.
  • Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes and Cancer, 29(1), 48-57.

To update your profile click here. For support on your academic profile contact .